An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

This outlook comes despite facing significant challenges, including the introduction of Stelara biosimilars, substantial foreign exchange headwinds, and changes to Medicare Part D that are ...

Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune <a target=_blank h ...

CEO David Cordani highlighted Cigna's full-year revenue growth of $247 billion, a 27% increase, alongside adjusted EPS of $27.33, which fell short of expectations. He reaffirmed the company's ...